Literature DB >> 23336300

A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia.

Ignacio Martin-Loeches, Antoni Torres.   

Abstract

The optimal length of antimicrobial therapy has not been extensively studied for a great majority of infections and, in critically ill patients affected by ventilator-associated pneumonia, is a persisting and unsolved issue confronting clinicians. The integration of biomarkers, clinical judgment, and microbiologic eradication might help to define a shorter duration for some ventilator-associated pneumonia episodes due to non-fermenting Gram-negative bacilli, but until these strategies are implemented in clinical practice for individualizing antibiotic treatment, a short-course duration does not seem to tailor a long benefit.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23336300      PMCID: PMC4057223          DOI: 10.1186/cc11899

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


  14 in total

Review 1.  Surrogate markers and microbiologic end points.

Authors:  Richard G Wunderink
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

2.  Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit.

Authors:  Miquel Ferrer; Adamantia Liapikou; Mauricio Valencia; Mariano Esperatti; Anna Theessen; Jose Antonio Martinez; Jose Mensa; Antoni Torres
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

3.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

4.  Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors.

Authors:  Ignacio Martin-Loeches; Maria Deja; Despoina Koulenti; George Dimopoulos; Brian Marsh; Antonio Torres; Michael S Niederman; Jordi Rello
Journal:  Intensive Care Med       Date:  2013-01-29       Impact factor: 17.440

5.  Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.

Authors:  E H Ibrahim; S Ward; G Sherman; R Schaiff; V J Fraser; M H Kollef
Journal:  Crit Care Med       Date:  2001-06       Impact factor: 7.598

6.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

7.  A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.

Authors:  Scott T Micek; Suzanne Ward; Victoria J Fraser; Marin H Kollef
Journal:  Chest       Date:  2004-05       Impact factor: 9.410

8.  Repeat bronchoalveolar lavage to guide antibiotic duration for ventilator-associated pneumonia.

Authors:  Eric W Mueller; Martin A Croce; Bradley A Boucher; Scott D Hanes; G Christopher Wood; Joseph M Swanson; Shanna K Chennault; Timothy C Fabian
Journal:  J Trauma       Date:  2007-12

9.  Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia.

Authors:  P Montravers; J Y Fagon; J Chastre; M Lecso; M C Dombret; J L Trouillet; C Gibert
Journal:  Am Rev Respir Dis       Date:  1993-01

10.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

Authors:  Jean Chastre; Michel Wolff; Jean-Yves Fagon; Sylvie Chevret; Franck Thomas; Delphine Wermert; Eva Clementi; Jesus Gonzalez; Dominique Jusserand; Pierre Asfar; Dominique Perrin; Fabienne Fieux; Sylvie Aubas
Journal:  JAMA       Date:  2003-11-19       Impact factor: 56.272

View more
  2 in total

Review 1.  Duration of antibiotic therapy in the intensive care unit.

Authors:  Gabor Zilahi; Mary Aisling McMahon; Pedro Povoa; Ignacio Martin-Loeches
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

2.  Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?

Authors:  Matteo Bassetti; Tobias Welte; Richard G Wunderink
Journal:  Crit Care       Date:  2016-01-29       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.